WO2008110914A3 - Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci - Google Patents

Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci Download PDF

Info

Publication number
WO2008110914A3
WO2008110914A3 PCT/IB2008/000628 IB2008000628W WO2008110914A3 WO 2008110914 A3 WO2008110914 A3 WO 2008110914A3 IB 2008000628 W IB2008000628 W IB 2008000628W WO 2008110914 A3 WO2008110914 A3 WO 2008110914A3
Authority
WO
WIPO (PCT)
Prior art keywords
libraries
methods
therefor
scfv antibodies
producing active
Prior art date
Application number
PCT/IB2008/000628
Other languages
English (en)
Other versions
WO2008110914A2 (fr
Inventor
Pierre Emile Ulysse Martineau
Etienne Weiss
Original Assignee
Inst Nat Sante Rech Med
Pierre Emile Ulysse Martineau
Etienne Weiss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pierre Emile Ulysse Martineau, Etienne Weiss filed Critical Inst Nat Sante Rech Med
Priority to EP08719320.7A priority Critical patent/EP2134841B9/fr
Priority to CA2681170A priority patent/CA2681170C/fr
Priority to US12/531,182 priority patent/US8841238B2/en
Priority to JP2009553231A priority patent/JP5385796B2/ja
Priority to ES08719320T priority patent/ES2384006T3/es
Priority to AT08719320T priority patent/ATE546524T1/de
Publication of WO2008110914A2 publication Critical patent/WO2008110914A2/fr
Publication of WO2008110914A3 publication Critical patent/WO2008110914A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des bibliothèques d'anticorps scFv, sur des anticorps isolés à partir des bibliothèques, et sur des procédés pour leur production et leur utilisation.
PCT/IB2008/000628 2007-03-15 2008-03-17 Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci WO2008110914A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08719320.7A EP2134841B9 (fr) 2007-03-15 2008-03-17 Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci
CA2681170A CA2681170C (fr) 2007-03-15 2008-03-17 Procedes de production d'anticorps scfv actifs et bibliotheques de ceux-ci
US12/531,182 US8841238B2 (en) 2007-03-15 2008-03-17 Methods for producing active scFv antibodies and libraries therefor
JP2009553231A JP5385796B2 (ja) 2007-03-15 2008-03-17 活性なｓｃＦｖ抗体及びそのライブラリーを生産する方法
ES08719320T ES2384006T3 (es) 2007-03-15 2008-03-17 Métodos para producir anticuerpos scFv activos y bibliotecas para los mismos
AT08719320T ATE546524T1 (de) 2007-03-15 2008-03-17 Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89494707P 2007-03-15 2007-03-15
US60/894,947 2007-03-15

Publications (2)

Publication Number Publication Date
WO2008110914A2 WO2008110914A2 (fr) 2008-09-18
WO2008110914A3 true WO2008110914A3 (fr) 2009-02-26

Family

ID=39760160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/000628 WO2008110914A2 (fr) 2007-03-15 2008-03-17 Procédés de production d'anticorps scfv actifs et bibliothèques de ceux-ci

Country Status (7)

Country Link
US (2) US8841238B2 (fr)
EP (1) EP2134841B9 (fr)
JP (1) JP5385796B2 (fr)
AT (1) ATE546524T1 (fr)
CA (1) CA2681170C (fr)
ES (1) ES2384006T3 (fr)
WO (1) WO2008110914A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012299A (es) * 2009-05-20 2012-03-29 Novimmune Sa Librerias de polipeptidos sinteticos y metodos para generar variantes de polipeptido naturalmente diversificadas.
EP2548030B1 (fr) * 2010-03-18 2015-05-27 Cornell University Préparation d'anticorps correctement pliés utilisant la présentation sur la membrane intérieure d'intermédiaires de translocation twin-arginine
WO2011130305A2 (fr) * 2010-04-12 2011-10-20 Sorrento Therapeutics Inc. Procédé pour afficher les anticorps
EP2752487A1 (fr) 2013-01-03 2014-07-09 Sanofi Criblage phénotypique intracellulaire
WO2015133882A1 (fr) * 2014-03-07 2015-09-11 사회복지법인 삼성생명공익재단 Banque d'anticorps scfv, son procédé de préparation et procédé de criblage d'anticorps scfv l'utilisant
EP3724378A4 (fr) 2017-12-11 2021-12-08 Abalone Bio, Inc. Présentation de protéines sur levure dans l'espace périplasmique
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045959A1 (fr) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Anticorps humanises et utilisations correspondantes
WO2000054057A1 (fr) * 1999-03-10 2000-09-14 Medical Research Council Selection d'immunoglobulines intracellulaires
WO2001048017A1 (fr) * 1999-12-28 2001-07-05 Esbatech Ag Intracorps a charpente definie stable dans un environnement reducteur et leurs applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6058338A (en) 1999-02-12 2000-05-02 Qualcomm Incorporated Method and apparatus for efficient GPS assistance in a communication system
US20040096826A1 (en) 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045959A1 (fr) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Anticorps humanises et utilisations correspondantes
WO2000054057A1 (fr) * 1999-03-10 2000-09-14 Medical Research Council Selection d'immunoglobulines intracellulaires
WO2001048017A1 (fr) * 1999-12-28 2001-07-05 Esbatech Ag Intracorps a charpente definie stable dans un environnement reducteur et leurs applications

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AUF DER MAUR ADRIAN ET AL: "Antigen-independent selection of intracellular stable antibody frameworks.", METHODS (SAN DIEGO, CALIF.) OCT 2004, vol. 34, no. 2, October 2004 (2004-10-01), pages 215 - 224, XP004526807, ISSN: 1046-2023 *
DER MAUR ADRIAN AUF ET AL: "Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 22 NOV 2002, vol. 277, no. 47, 22 November 2002 (2002-11-22), pages 45075 - 45085, XP002284890, ISSN: 0021-9258 *
JUNG S ET AL: "IMPROVING IN VIVO FOLDING AND STABILITY OF A SINGLE-CHAIN FV ANTIBODY FRAGMENT BY LOOP GRAFTING", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 8, 1 January 1997 (1997-01-01), pages 959 - 966, XP000971779, ISSN: 0269-2139 *
LADEN JEAN-CHARLES ET AL: "Expression and folding of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm.", RESEARCH IN MICROBIOLOGY SEP 2002, vol. 153, no. 7, September 2002 (2002-09-01), pages 469 - 474, XP002509241, ISSN: 0923-2508 *
MARTINEAU P ET AL: "Expression of an antibody fragment at high levels in the bacterial cytoplasm", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 280, no. 1, 3 July 1998 (1998-07-03), pages 117 - 127, XP004453942, ISSN: 0022-2836 *
MARTINEAU P ET AL: "IN VITRO FOLDING AND THERMODYNAMIC STABILITY OF AN ANTIBODY FRAGMENT SELECTED IN VIVO FOR HIGH EXPRESSION LEVELS IN ESCHERICHIACOLI CYTOPLASM", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 292, 1 October 1999 (1999-10-01), pages 921 - 929, XP004462583, ISSN: 0022-2836 *
PHILIBERT PASCAL ET AL: "A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.", BMC BIOTECHNOLOGY 2007, vol. 7, 22 November 2007 (2007-11-22), pages 81, XP002509301, ISSN: 1472-6750 *

Also Published As

Publication number Publication date
US20090143247A1 (en) 2009-06-04
EP2134841B9 (fr) 2014-06-11
CA2681170C (fr) 2017-10-31
WO2008110914A2 (fr) 2008-09-18
ATE546524T1 (de) 2012-03-15
EP2134841B1 (fr) 2012-02-22
EP2134841A2 (fr) 2009-12-23
US8841238B2 (en) 2014-09-23
JP5385796B2 (ja) 2014-01-08
JP2010521447A (ja) 2010-06-24
CA2681170A1 (fr) 2008-09-18
ES2384006T3 (es) 2012-06-28
US20100167957A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2007129895A3 (fr) Anticorps monoclonal antagoniste anti-cd40 humain
WO2007008943A3 (fr) Proteines optimisees qui ciblent la molecule ep-cam
WO2009112245A9 (fr) Anticorps contre le csf-1r
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
AU2008257801A8 (en) RSV-specific binding molecules and means for producing them
WO2008052187A3 (fr) Anticorps et immunoconjugués, et leurs utilisations
WO2007106744A8 (fr) Anticorps anti-5t4 et leurs utilisations
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2007120334A3 (fr) Méthodes et compositions de ciblage de la polyubiquitine
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2008091954A3 (fr) Anticorps cd40 optimisés et leurs procédés d'utilisation
WO2009126350A3 (fr) Procédés et compositions pour cibler la polyubiquitine
EP1761566A4 (fr) Anticorps monoclonaux humanises anti-tag-72
WO2008048970A8 (fr) Anticorps synthétiques
WO2009135181A3 (fr) Procédé et compositions pour préparer des anticorps et des dérivés d'anticorps avec une fucosylation centrale réduite
NL1032452A1 (nl) Menselijke monoklonale antilichamen tegen activine receptor-achtig kinase-1.
WO2006028936A3 (fr) Molecules heteromultimeriques
WO2007140371A8 (fr) Anticorps et immuno-conjugués, et leurs utilisations
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2008027236A3 (fr) Anticorps multispécifiques
IL190472A (en) Glyphican Antibody 3 Methods for their preparation and use
WO2007049152A3 (fr) Procedes pour produire des lymphocytes b stables
WO2008048519A3 (fr) Anticorps se liant aux épitopes de cxcr7

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2681170

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009553231

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008719320

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719320

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12531182

Country of ref document: US